

All RCE abstracts: abstracts of interest as identified through tabular results

Title of abstract (primary abstract in green)	Similarity Score
NERCE project 2A MRCE bbstract 12: goldman GLRCE animal models and correlates of immunity for plague SERCEB abstract 16 4.1	0.30614 0.26664 0.23056
NERCE project 3 NBC abstract 7 salmonella type III secretion for biodefense vaccines MARCE abstract 4 rp1.4 salmonella typhi-based anthrax vaccine compatible with prime-boost strategy SERCEB abstract 10 project 1.3 anti-orthopox immunomodulatory molecule vaccine	0.29673 0.27396 0.24714
NERCE project 4 MARCE abstract 10 multivalent f. tularensis capsule/protein conjugate vaccines SERCEB abstract 10 project 1.3 anti-orthopox immunomodulatory molecule vaccine MRCE abstract 10	0.30131 0.29614 0.26012
NERCE project 1a GLRCE therapeutic inhibition of b. anthracis pathogenesis NBC abstract 2 b cell related intervention WRCE bacillus anthracis-host interactions	0.28708 0.27067 0.25089
SERCEB abstract 8 project 1.1 WRCE discovery of subunit vaccines for smallpox MRCE abstract 9 project 11 MRCE abstract 7 project stanley	0.3162 0.28778 0.2812
SERCEB abstract 10 project 1.3 anti-orthopox immunomodulatory molecule vaccine MRCE abstract 2 project 5 fremont MARCE abstract 7 poxvirus subproject 1: subunit vaccines NERCE project 4	0.33395 0.29624 0.29614
SERCEB abstract 16 4.1 NBC abstract 5 antibodies to the yop translocon and immunity to plague GLRCE a putative virulence factor in yersinia GLRCE immunity to yersinia pestis infections	0.29468 0.27874 0.27604
MARCE abstract 1 rp 1.1 b. anthracis spore antigens MARCE abstract 2 rp 1.2 vegetative phase antigens of b. anthracis as a multivalent vaccine for anthrax WRCE cell wall proteins in bacillus anthracis as vaccines NBC anstract 6 theme 3 crystal	0.31954 0.30731 0.28251
MARCE abstract 3 project 1.3 actions and interactions of the toxins of b. anthracis WRCE bacillus anthracis-host interactions NBC abstract 17 role of tissue-specific cell killing in anthrax toxin-mediated cell killing MARCE abstract 11 subproject 4.2 innate and adaptive immune responses to francisella tularensis	0.31645 0.30482 0.24466
MARCE abstract 7 poxvirus subproject 1 subunit vaccines MARCE abstract 8 poxvirus subproject 3 targets of VIG MRCE abstract 30 project 8 kazura SERCEB abstract 10 project 1.3 anti-orthopox immunomodulatory molecule vaccine	0.33258 0.31988 0.29624
MARCE abstract 12 rp 4.3 designd of a rationally-attenuated, mucosally-administered f. tularensis vaccine strain MARCE abstract 15 rp 4.31 therapies for tularemia WRCE revealing the attenuating mutations of f. tularensis LVS WRCE development and evaluation of human brucellosis vaccines	0.41407 0.3868 0.26232
MARCE abstract 15 rp 4.31 therapies for tularemia MARCE abstract 12 rp 4.3 designd of a rationally-attenuated, mucosally-administered f. tularensis vaccine strain WRCE revealing the attenuating mutations of f. tularensis LVS MARCE abstract 10 multivalent f. tularensis capsule/protein conjugate vaccines	0.41407 0.39096 0.28471
MRCE abstract 2 project 5 fremont SERCEB abstract 10 project 1.3 antioorthopox immunomodulatory molecule vaccine SERCEB abstrac 14 3.1 MRCE abstract 15 project 17 colonna, marco	0.33395 0.25096 0.25048
MRCE abstract 4 project 4 MRCE abstract 27 project 2 atkinson MARCE abstract 9 project 3.4 ectomelia pathogenesis MARCE abstract 35 flaviviruses: west nile virus	0.30738 0.29451 0.26341
MRCE abstract 5 project 6 virgin NBC abstract 14 MRCE abstract 7 project 9 - stanley GLRCE development of antiviral strategies	0.30751 0.29417 0.27457
MRCE abstract 7 project 9 stanley MRCE abstract 9 project 11 MRCE abstact 3 project 1 yokoyama MRCE abstract 5 project 6 virgin	0.32057 0.29521 0.29417
MRCE abstract 9 project 11 MRCE abstract 7 project 9 stanley MRCE abstract 30 project 8 kazura MARCE abstract 7 poxvirus subproject 1 subunit vaccines	0.32067 0.31816 0.2932
MRCE abstract 12 project 12 goldman NERCE project 2a SERCEB abstract 16 4.1 GLRCE immunity to yersinia pestis infections	0.30614 0.26384 0.24222
MRCE abstract 17 project 19 fan WRCE recombinant envelope protein domain III as a candidate subunit dengue vaccine WRCE vaccine for rocky mountain spotted fever WRCE development of novel pseudoinfectious flavivirus vaccines	0.3617 0.2706 0.25117
MRCE abstract 28 project 20 molina, hector MRCE abstract 27 project 2 atkinson MRCE abstract 4 project 4 SERCEB abstract 10 project 1.3 antioorthopox immunomodulatory molecule vaccine	0.34586 0.26155 0.22678
NBC abstract 5 antibodies to the yop translocon and immunity to plague GLRCE immunity to yersinia pestis infections GLRCE animal models and correlates of immunity for plague SERCEB anstract 16 4.1	0.3419 0.31181 0.29468
NBC anstract 11 identification and characterization of IFN-antagonists: critical virulence factors GLRCE prevention and control of ebola virus infection NBC abstract 12 role of dengue virus non-structural proteins in inhibiting innate immunity SERCEB anstract 10 project 1.3 antioorthopox immunomodulatory molecule vaccine	0.32567 0.27907 0.26858
GLRCE revention and control of ebola virus infection NBC abstract 11 identification and characterization of T+IFN antagonists: critical virulence factors GLRCE a screening system for antivirals MRCE abstract 18 project 21 olivo, p	0.32657 0.29186 0.27337
WRCE alphavirus vaccines for biodefense WRCE novel genetic tools for viral biodefense WRCE rational design and optimization of live-attenuated vaccines for alphaviral encephalitides WRCE recombinant envelope protein domain III as a candidate subunit dengue vaccine	0.31305 0.25843 0.24249
WRCE discovery of subunit vaccines for smallpox SERCEB abstract 8 project 1.1 WRCE discovery of subunit vaccine candidates against glanders MARCE abstract 7 poxvirus subproject 1 subunit vaccines	0.3162 0.30765 0.26348

Table 3-1: Highly correlative abstracts